2/3
07:52 am
ivvd
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration [Yahoo! Finance]
Low
Report
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration [Yahoo! Finance]
2/3
07:01 am
ivvd
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
Medium
Report
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
1/24
03:28 pm
ivvd
How Recent Price Target Resets Are Rewriting The Story For Invivyd (IVVD) [Yahoo! Finance]
Medium
Report
How Recent Price Target Resets Are Rewriting The Story For Invivyd (IVVD) [Yahoo! Finance]
1/22
10:45 am
ivvd
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention [Yahoo! Finance]
Low
Report
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention [Yahoo! Finance]
1/22
07:01 am
ivvd
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention
Low
Report
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention
1/21
07:17 am
ivvd
Invivyd (NASDAQ:IVVD) had its "buy" rating reaffirmed by analysts at BTIG Research.
Medium
Report
Invivyd (NASDAQ:IVVD) had its "buy" rating reaffirmed by analysts at BTIG Research.
1/20
07:01 am
ivvd
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
Medium
Report
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
1/14
02:21 pm
ivvd
?Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 [Yahoo! Finance]
Medium
Report
?Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 [Yahoo! Finance]
1/13
12:56 pm
ivvd
Adimab Records Another Year of Double-Digit Clinical Program Growth [Yahoo! Finance]
Low
Report
Adimab Records Another Year of Double-Digit Clinical Program Growth [Yahoo! Finance]
1/9
07:38 pm
ivvd
Why Analysts See Invivyd (IVVD) Story Shifting After REVOLUTION Program And US$10 Target [Yahoo! Finance]
Medium
Report
Why Analysts See Invivyd (IVVD) Story Shifting After REVOLUTION Program And US$10 Target [Yahoo! Finance]
1/8
07:01 am
ivvd
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
Low
Report
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
12/31
11:21 am
ivvd
BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311's Superior Market Potential Over Pemgarda [Yahoo! Finance]
Low
Report
BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311's Superior Market Potential Over Pemgarda [Yahoo! Finance]
12/25
07:00 pm
ivvd
Does Invivyd's (IVVD) Index Debut Reveal a Turning Point in Its Biotech Credibility? [Yahoo! Finance]
Medium
Report
Does Invivyd's (IVVD) Index Debut Reveal a Turning Point in Its Biotech Credibility? [Yahoo! Finance]
12/24
06:15 am
ivvd
Invivyd (NASDAQ:IVVD) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Low
Report
Invivyd (NASDAQ:IVVD) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
12/23
08:12 am
ivvd
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID [Yahoo! Finance]
Medium
Report
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID [Yahoo! Finance]
12/23
08:12 am
ivvd
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID [Yahoo! Finance]
Medium
Report
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID [Yahoo! Finance]
12/23
07:05 am
ivvd
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Medium
Report
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
12/23
07:01 am
ivvd
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Low
Report
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
12/23
05:31 am
ivvd
Invivyd (IVVD): Assessing Valuation After S&P Biotechnology Select Industry Index Inclusion [Yahoo! Finance]
Low
Report
Invivyd (IVVD): Assessing Valuation After S&P Biotechnology Select Industry Index Inclusion [Yahoo! Finance]
12/22
06:01 am
ivvd
Invivyd (NASDAQ:IVVD) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
High
Report
Invivyd (NASDAQ:IVVD) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
12/19
01:33 am
ivvd
How Recent Clinical Progress Is Rewriting the Story for Invivyd [Yahoo! Finance]
Low
Report
How Recent Clinical Progress Is Rewriting the Story for Invivyd [Yahoo! Finance]
12/16
04:38 pm
ivvd
Invivyd (NASDAQ:IVVD) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Invivyd (NASDAQ:IVVD) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/30
12:41 am
ivvd
A Look at Invivyd (IVVD) Valuation After Advancing VBY329 RSV Antibody Candidate into Preclinical Development [Yahoo! Finance]
Low
Report
A Look at Invivyd (IVVD) Valuation After Advancing VBY329 RSV Antibody Candidate into Preclinical Development [Yahoo! Finance]
11/27
02:49 pm
ivvd
Invivyd (NASDAQ:IVVD) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Invivyd (NASDAQ:IVVD) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
06:43 am
ivvd
Invivyd (NASDAQ:IVVD) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.
Low
Report
Invivyd (NASDAQ:IVVD) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.